Replimune to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology
September 26 2018 - 8:00AM
Replimune Group Inc. (NASDAQ: REPL), a biotechnology company
developing oncolytic immunotherapies derived from its Immulytic™
platform, today announced that Robert Coffin, Ph.D., Chief
Executive Officer and Director of Replimune, will present at the
Leerink Partners Roundtable Series: Rare Disease & Oncology on
Wednesday, October 3, 2018 at 11:30 AM ET at the Lotte New York
Palace Hotel in New York, NY.
About Replimune
Replimune Group Inc., headquartered in Woburn, MA, was founded
in 2015 to develop the next generation of “oncolytic
immunotherapies” for the treatment of cancer. Replimune is
developing novel, proprietary therapeutics intended to improve the
direct cancer-killing effects of selective virus replication and
the potency of the immune response to the tumor antigens released.
The Company’s Immulytic™ platform is designed to maximize systemic
immune activation, in particular to tumor neoantigens, through
robust viral mediated immunogenic tumor cell killing and the
delivery of optimal combinations of immune-activating proteins to
the tumor and draining lymph nodes. The approach is expected to be
highly synergistic with immune checkpoint blockade and other
approaches to cancer treatment. Replimune intends to progress these
therapies rapidly through clinical development in combination with
other immuno-oncology products with complementary mechanisms of
action. For more information, please visit
www.replimune.com.
Replimune ContactPamela Esposito,
Ph.D.Replimune Group Inc.617.233.6988pamela@replimune.com
Investor Inquiries Chris BrinzeyWestwicke
Partners339.970.2843chris.brinzey@westwicke.com
Media InquiriesArleen Goldenberg Verge
Scientific
Communications917.548.1582agoldenberg@vergescientific.com
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Sep 2023 to Sep 2024